INTRACAVERNOSAL INJECTIONS AND FIBROSIS: MYTH OR REALITY?
Authors:
- 5 August 2008
- journal article
- Published by Wiley in BJU International
- Vol. 102 (5) , 525-526
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Assessment of comparative treatment satisfaction with sildenafil citrate and penile injection therapy in patients responding to bothBJU International, 2007
- In vitro viability of human cavernosal endothelial and fibroblastic cells after exposure to papaverine/phentolamine and prostaglandin E1BJU International, 2005
- Cytotoxicity of different intracavernous vasoactive drugs on cultured endothelial cells of human corpus cavernosum penisUrology, 2004
- Preference for oral sildenafil or intracavernosal injection in patients with erectile dysfunction already using intracavernosal injection for > 1 yearBJU International, 2003
- Use of Medications for Erectile Dysfunction in the United States, 1996 Through 2001Journal of Urology, 2003
- Vasoactive agents induce cytotoxicity in cultured human penile smooth muscle cellsUrology, 2002
- Short-term histopathologic effects of different intracavernosal agents on corpus cavernosum and antifibrotic activity of intracavernosal verapamil: an experimental studyUrology, 2001
- Efficacy and Safety of Intracavernosal Alprostadil in Men with Erectile DysfunctionNew England Journal of Medicine, 1996
- Cavernosal Alpha-Blockade: A New Technique for Investigating and Treating Erectile ImpotenceThe British Journal of Psychiatry, 1983
- INTRACAVERNOUS INJECTION OF PAPAVERINE FOR ERECTILE FAILUREThe Lancet, 1982